Abstract:Journal of Gastroenterology and HepatologyVolume 35, Issue 10 p. 1836-1838 Letter to the Editor RNA conversion of COVID-19 in respiratory and alimentary specimens during asymptomatic convalescence Yichi Zhang, Yichi Zhang orcid.org/0000-0002-9332-4316 Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorTingting Su, Tingting Su Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi, China These authors contributed equally to this study.Search for more papers by this authorBing Han, Bing Han Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorMiao Huang, Miao Huang Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorXueshi Zhou, Xueshi Zhou Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi, ChinaSearch for more papers by this authorJian Wang, Jian Wang Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYuanwang Qiu, Yuanwang Qiu [email protected] Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi, China These authors contributed equally to this study.Search for more papers by this authorYingbin Liu, Yingbin Liu [email protected] orcid.org/0000-0002-1075-1890 Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorJinyang Gu, Corresponding Author Jinyang Gu [email protected] orcid.org/0000-0003-2727-2420 Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study. Correspondence Dr Jinyang Gu, Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected] Dr Yingbin Liu, Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected] Dr Yuanwang Qiu, Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi 214011, China. Email: [email protected]Search for more papers by this author Yichi Zhang, Yichi Zhang orcid.org/0000-0002-9332-4316 Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorTingting Su, Tingting Su Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi, China These authors contributed equally to this study.Search for more papers by this authorBing Han, Bing Han Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorMiao Huang, Miao Huang Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorXueshi Zhou, Xueshi Zhou Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi, ChinaSearch for more papers by this authorJian Wang, Jian Wang Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYuanwang Qiu, Yuanwang Qiu [email protected] Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi, China These authors contributed equally to this study.Search for more papers by this authorYingbin Liu, Yingbin Liu [email protected] orcid.org/0000-0002-1075-1890 Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study.Search for more papers by this authorJinyang Gu, Corresponding Author Jinyang Gu [email protected] orcid.org/0000-0003-2727-2420 Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China These authors contributed equally to this study. Correspondence Dr Jinyang Gu, Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected] Dr Yingbin Liu, Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected] Dr Yuanwang Qiu, Infectious Disease Department, The Wuxi Fifth Affiliated Hospital of Jiangnan University, Wuxi 214011, China. Email: [email protected]Search for more papers by this author First published: 14 May 2020 https://doi.org/10.1111/jgh.15095 Declaration of conflict of interest: None declared. Author contribution: YQ, YL, and JG created the study concept. TS, BH, XZ, and JW performed the data collection. YZ, TS, BH, and MH conducted the data analysis. YZ, BH, and MH wrote the manuscript. YQ, YL, and JG checked the manuscript. All authors approved the final version for publication. Ethical approval: This study was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (no. XHEC-C-2020-079) and the Wuxi Fifth Affiliated Hospital of Jiangnan University (no. 2020-004-1). Informed consent: Written informed consent was waived. Financial support: This work was supported by grant from the National Natural Science Foundation of China (81772507 to JG). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Ling Y, Xu SB, Lin YX et al. Persistence and clearance of viral RNA in 2019 novel coronavirus. Chin Med J (Engl) Epub ahead of print 2020; 133(9): 1039–1043. https://doi.org/10.1097/CM9.0000000000000774 10.1097/CM9.0000000000000774 PubMedWeb of Science®Google Scholar 2Zhang W, Du RH, Li B et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020; 9: 386–389. https://doi.org/10.1080/22221751.2020.1729071 10.1080/22221751.2020.1729071 CASPubMedWeb of Science®Google Scholar 3Xie C, Lu J, Wu D, Zhao H, Rao B, Yang Z. False negative rate of COVID-19 is eliminated by using nasal swab test. Travel Med Infect Dis Epub ahead of print 11 Apr 2020. https://doi.org/10.1016/j.tmaid.2020.101668 10.1016/j.tmaid.2020.101668 PubMedWeb of Science®Google Scholar 4Zou L, Ruan F, Huang M. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177–1179. https://doi.org/10.1056/NEJMc2001737 10.1056/NEJMc2001737 PubMedWeb of Science®Google Scholar 5Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, Zhang Q, Qi W. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut Epub ahead of print: 26 Feb 2020. 69(6): 1141-3 doi:https://doi.org/10.1136/gutjnl-2020-320832 10.1136/gutjnl-2020-320832 CASPubMedWeb of Science®Google Scholar 6Song Y, Liu P, Shi XL et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut Epub ahead of print 5 Mar 2020; 69: 1143–1144. https://doi.org/10.1136/gutjnl-2020-320891 10.1136/gutjnl-2020-320891 CASPubMedWeb of Science®Google Scholar 7Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology Epub ahead of print 3 Mar 2020; 158: 1518–1519. https://doi.org/10.1053/j.gastro.2020.02.054 10.1053/j.gastro.2020.02.054 CASPubMedWeb of Science®Google Scholar 8Xu Y, Li X, Zhu B et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med Epub ahead of print 13 Mar 2020; 26: 502–505. https://doi.org/10.1038/s41591-020-0817-4 10.1038/s41591-020-0817-4 CASPubMedWeb of Science®Google Scholar 9Chen D, Xu W, Lei Z et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int J Infect Dis Epub ahead of print 2020; 93: 297–299. https://doi.org/10.1016/j.ijid.2020.03.003 10.1016/j.ijid.2020.03.003 CASPubMedWeb of Science®Google Scholar 10Lan L, Xu D, Ye G et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA Epub ahead of print 27 Feb 2020. https://doi.org/10.1001/jama.2020.2783 10.1001/jama.2020.2783 PubMedWeb of Science®Google Scholar 11Xie C, Jiang L, Huang G et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis Epub ahead of print 2020; 93: 264–267. https://doi.org/10.1016/j.ijid.2020.02.050 10.1016/j.ijid.2020.02.050 CASPubMedWeb of Science®Google Scholar 12Lipsitch M, Kahn R, Mina MJ. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials. Nat Med Epub ahead of print 27 Apr 2020. https://doi.org/10.1038/s41591-020-0887-3 10.1038/s41591-020-0887-3 Web of Science®Google Scholar Volume35, Issue10October 2020Pages 1836-1838 ReferencesRelatedInformation

Abstract:Future VirologyVol. 8, No. 1 EditorialFree AccessDevelopment of SARS vaccines and therapeutics is still neededShibo Jiang, Lu Lu & Lanying DuShibo Jiang* Author for correspondenceKey Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, China. Search for more papers by this authorEmail the corresponding author at shibojiang@fudan.edu.cn, Lu LuKey Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, ChinaSearch for more papers by this author & Lanying DuThe Lindsley F Kimball Research Institute, The New York Blood Center, New York, NY 10065, USASearch for more papers by this authorPublished Online:20 Dec 2012https://doi.org/10.2217/fvl.12.126AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: HCoV-EMChuman coronavirusreceptor-binding domainSARSSARS-CoVspike proteintherapeuticsvaccinesOn 22 September 2012, the WHO was informed by the UK of a case of acute respiratory syndrome with renal failure [101]. The patient had a travel history to the Kingdom of Saudi Arabia, where a 60 year-old Saudi national died from a similar disease earlier in 2012. The causative pathogen, a novel human Betacoronavirus (HCoV-EMC), was quickly identified from the sputum samples of the earlier case [1] and the gene sequence of this virus was 99.5% identical to that of the virus isolated from clinical samples of the later case.The outbreak of HCoV-EMC infection in Saudi Arabia has raised great concerns about the potential pandemic of the SARS-like disease, and strategies for combating this newly emerged infectious disease should be prepared [2]. It is believed that the existing SARS research may provide a useful template for developing vaccines and therapeutics against HCoV-EMC infection [3], but so far, no effective anti-SARS vaccines and therapeutics have been well developed.SARS, which is caused by the SARS coronavirus (SARS-CoV), emerged from China and caused nearly 8500 cases and 916 deaths during the outbreak in 2002 and 2003 [3–5]. Although SARS is currently under control, the possibility of a new SARS outbreak remains a global concern because of the potential for zoonotic transmission of SARS-CoV or SARS-CoV-like viruses from their natural hosts to humans, or the accidental or intentional release of laboratory SARS-CoV strains [6]. Therefore, developing vaccines and therapeutics for the prevention and treatment of SARS is still a matter of urgency.During the global 2002/2003 SARS pandemic, many foundations, pharmaceutical companies and governments provided abundant funds to support the development of anti-SARS vaccines and therapeutics. However, after the disappearance of SARS, these funds were either withdrawn or discontinued because of the lack of a sustainable market of the products to be developed.A number of inactivated and live-attenuated SARS vaccines, as well as those based on vectors encoding the full-length S protein of SARS-CoV, showed high immunogenicity in inducing neutralizing antibody responses and protection against SARS-CoV challenge [6]. However, most of these vaccine candidates may also induce immunopathology or other harmful immune responses [7,8], raising concerns about their safety. On the other hand, recombinant proteins containing the receptor-binding domain of the SARS-CoV S protein could be developed as a safe and effective SARS vaccine. This potential is based on the ability of receptor binding domain-based vaccine to induce stronger cross-neutralizing antibody responses and protection against SARS-CoV [9], with a correspondingly lower probability of inducing immunopathology, in contrast with the other SARS vaccine candidates mentioned previously [6].So far, no specific anti-SARS drugs have been developed. A number of drug candidates, including the SARS-CoV fusion inhibitors [10], proteinase (e.g., 3C-like cysteine proteinase) inhibitors, PLpro inhibitors, RNA-dependent RNA polymerase inhibitors, helicase inhibitors, siRNAs inhibiting SARS-CoV structural proteins E, M and N, and therapeutic antibodies, have been developed in laboratory and preclinical studies [11]. However, none of them have been forwarded to clinical trials, possibly for the same reasons as previously described for vaccine development.Apart from financial support, another main challenge for the clinical development of anti-SARS vaccines is the lack of endemic SARS and the lethal nature of the disease. It is not ethical to conduct human efficacy studies by exposing healthy human volunteers to a lethal agent like SARS-CoV. Fortunately, however, according to the ‘Animal Rule’, a pivotal animal efficacy study can be conducted for evaluating the in vivo efficacy of the anti-SARS vaccines using two animal species that exhibit pathophysiology of the disease and host immune responses that closely match those of humans [12]. The data from these animal experiments can then be considered by the US FDA as evidence of effectiveness of the tested vaccine.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.References1 Zaki AM, van Boheemen S, Bestebroer TM et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med.367(19),1814–1820 (2012).Crossref, Medline, CAS, Google Scholar2 Anderson LJ, Baric RS. Emerging human coronaviruses: disease potential and preparedness. N. Engl. J. Med.367(19),1850–1852 (2012).Crossref, Medline, CAS, Google Scholar3 Butler D. SARS veterans tackle coronavirus. Nature490(7418),20 (2012).Crossref, Medline, CAS, Google Scholar4 Zhong NS, Zheng BJ, Li YM et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet362(9393),1353–1358 (2003).Crossref, Medline, CAS, Google Scholar5 Peiris JSM, Lai ST, Poon LLM et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet361(9366),1319–1325 (2003).Crossref, Medline, CAS, Google Scholar6 Du L, He Y, Zhou Y et al. The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat. Rev. Microbiol.7(3),226–236 (2009).Crossref, Medline, CAS, Google Scholar7 Weingartl H, Czub M, Czub S et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol.78(22),12672–12676 (2004).Crossref, Medline, CAS, Google Scholar8 Tseng CT, Sbrana E, Iwata-Yoshikawa N et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One7(4),e35421 (2012).Crossref, Medline, CAS, Google Scholar9 He Y, Li J, Li W et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol.176(10),6085–6092 (2006).Crossref, Medline, CAS, Google Scholar10 Liu S, Xiao G, Chen Y et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet363(9413),938–947 (2004).Crossref, Medline, CAS, Google Scholar11 Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol.6(5),615–631 (2011).Link, Google Scholar12 Burns DL. Licensure of vaccines using the animal rule. Curr. Opin. Virol.2(3),353–356 (2012).Crossref, Medline, Google Scholar101 WHO. Global Alert and Response. www.who.int/csr/don/2012_09_23/en/index.htmlGoogle ScholarFiguresReferencesRelatedDetailsCited ByImmunogenicity of a secreted, C-terminally truncated, form of bovine viral diarrhea virus E2 glycoprotein as a potential candidate in subunit vaccine development6 January 2023 | Scientific Reports, Vol. 13, No. 1Immune Response to SARS-CoV-2 Vaccines21 June 2022 | Biomedicines, Vol. 10, No. 7The Coronavirus pandemic – 2022: Viruses, variants & vaccinesCytokine & Growth Factor Reviews, Vol. 63Coronavirus (SARS-CoV-2): a systematic review for potential vaccines5 February 2021 | Human Vaccines & Immunotherapeutics, Vol. 18, No. 1Meta-analysis and comprehensive study of coronavirus outbreaks: SARS, MERS and COVID-19Journal of Infection and Public Health, Vol. 14, No. 8Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses28 May 2021 | Frontiers in Immunology, Vol. 12Surging publications on the COVID-19 pandemicClinical Microbiology and Infection, Vol. 27, No. 3Revisiting potential druggable targets against SARS‐CoV ‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review6 July 2020 | Drug Development Research, Vol. 81, No. 8Adjuvants for Coronavirus Vaccines6 November 2020 | Frontiers in Immunology, Vol. 11Potential strategies for combating COVID-1910 August 2020 | Archives of Virology, Vol. 165, No. 11COVID-19 (An International Trauma): A Brief Analysis on Research Trends, Impacts and Solutions11 April 2020 | International Journal For Research in Applied Sciences and Biotechnology, Vol. 07, No. 02Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatmentJournal of Research in Medical Sciences, Vol. 25, No. 1Demonstration Study: A Protocol to Combine Online Tools and Databases for Identifying Potentially Repurposable Drugs4 May 2017 | Data, Vol. 2, No. 2Environmental risks in a diffusive SIS model incorporating use efficiency of the medical resourceDiscrete and Continuous Dynamical Systems - Series B, Vol. 21, No. 5Cell adhesion as a novel approach to determining the cellular binding motif on the severe acute respiratory syndrome coronavirus spike proteinJournal of Virological Methods, Vol. 201 Vol. 8, No. 1 STAY CONNECTED Metrics History Published online 20 December 2012 Published in print January 2013 Information© Future Medicine LtdKeywordsHCoV-EMChuman coronavirusreceptor-binding domainSARSSARS-CoVspike proteintherapeuticsvaccinesFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download

The Wuhan SARS‐CoV‐2—What's Next for China

Influenza‐like Illnesses Caused by a Cluster of Imported Italian COVID‐19

The Progress of 2019 Novel Coronavirus Event in China

A Survey of 434 Clinical Trials about Coronavirus Disease 2019 in China

Corrigendum To: Genomic Diversity of Severe Acute Respiratory Syndrome–Coronavirus 2 in Patients with Coronavirus Disease 2019

2019 Novel Coronavirus Infection and Gastrointestinal Tract

RNA Conversion of COVID‐19 in Respiratory and Alimentary Specimens During Asymptomatic Convalescence

Detection of Antibodies Against SARS‐CoV‐2 in Patients with COVID‐19

Development of SARS Vaccines and Therapeutics is Still Needed

Outbreak of Pneumonia of Unknown Etiology in Wuhan, China: the Mystery and the Miracle

Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding

Possibly Critical Role of Wearing Masks in General Population in Controlling COVID‐19

Global Health Concerns Stirred by Emerging Viral Infections

A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein

Influence of COVID‐19 in Patients with Concurrent Tuberculosis Coinfections

Game Consumption and the 2019 Novel Coronavirus

Therapeutic and Triage Strategies for 2019 Novel Coronavirus Disease in Fever Clinics

Population Serology for SARS-CoV-2 is Essential to Regional and Global Preparedness

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Fear of Disease Progression and Psychological Stress in Cancer Patients under the Outbreak of COVID‐19